Compare WOR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOR | BEAM |
|---|---|---|
| Founded | 1955 | 2017 |
| Country | United States | United States |
| Employees | 3400 | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 1994 | 2019 |
| Metric | WOR | BEAM |
|---|---|---|
| Price | $56.74 | $29.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $59.50 | $50.75 |
| AVG Volume (30 Days) | 133.1K | ★ 1.8M |
| Earning Date | 03-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $1,153,762,000.00 | $24,000.00 |
| Revenue This Year | $22.21 | N/A |
| Revenue Next Year | $6.03 | $33.77 |
| P/E Ratio | $26.70 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $45.01 | $15.60 |
| 52 Week High | $70.91 | $36.44 |
| Indicator | WOR | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 58.31 | 47.89 |
| Support Level | $51.93 | $28.50 |
| Resistance Level | $58.56 | $33.15 |
| Average True Range (ATR) | 1.47 | 2.05 |
| MACD | 0.20 | -0.01 |
| Stochastic Oscillator | 77.52 | 40.12 |
Worthington Enterprises Inc is a designer and manufacturer of products and services, including manufactured metal products. The company operates under two reportable operating segments: Consumer Products and Building Products. The consumer Products business has a diverse product offering in the tools, outdoor living and celebrations categories, including propane-filled cylinders for torches, handheld torches, specialized hand tools, drywall tools, accessories and gas grills, and others. And the Building Products business engaged in providing pressurized containment solutions, providing critical components in the residential, non-residential, and repair and remodel end markets through essential categories. The company derives majority of the revenue from Building Products segment.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.